Avante Corp. achieved 8.2% year-over-year revenue growth in fiscal third quarter ended December 31, 2025, including 12.4% increase in recurring revenueThe Company achieved Adjusted EBITDA of $0.82 mil ...
The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果